AIU – Faculty of Pharmacy
Published January 1, 2026 | Version v1
Journal article Restricted

Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study

Description

nan

Original Publication: https://doi.org/10.1038/S41591-025-04077-9

Note: This record is metadata-only as the original article may be subject to publisher restrictions.



This version is archived in the Arab International University (AIU) repository for open access and dissemination purposes. The content of this paper has not been modified from the original publication.
For more information, please visit the official repository of Arab International University (AIU):

https://aiu.edu.sy

Notes

Journal: Nature Medicine. Publisher: Springer Science and Business Media LLC

Files

Restricted

The record is publicly accessible, but files are restricted. Log in to check if you have access.

Additional details

Identifiers

DOI
10.1038/S41591-025-04077-9

References

  • Cho, M. H. et al. A genome-wide association study of emphysema and airway quantitative imaging phenotypes. Am. J. Respir. Crit. Care Med. 192, 559–569 (2015).
  • Soriano, J. B. et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir. Med. 8, 585–596 (2020).
  • Momtazmanesh, S. et al. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019. eClinicalMedicine 59, 101936 (2023).
  • Hay, S. I. et al. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1873–1922 (2025).
  • Bousquet, J., Dahl, R. & Khaltaev, N. Global Alliance against Chronic Respiratory Diseases. Eur. Respir. J. 29, 233–239 (2007.
  • Greene, C. M. & Abdulkadir, M. Global respiratory health priorities at the beginning of the 21st century. Eur. Respir. Rev. 33, 230205 (2024).
  • Bender, R. G. et al. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect. Dis. 24, 974–1002 (2024).
  • Ledesma, J. R. et al. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Infect. Dis. 24, 698–725 (2024).
  • Gravely, S. et al. Implementation of key demand-reduction measures of the WHO Framework Convention on Tobacco Control and change in smoking prevalence in 126 countries: an association study. Lancet Public Health 2, e166–e174 (2017).
  • Reddel, H. K. et al. Global Initiative for Asthma Strategy 2021: Executive Summary and rationale for key changes. Am. J. Respir. Crit. Care Med. 205, 17–35 (2022).
  • Ferguson, G. T. et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir. Med. 6, 747–758 (2018).
  • Martinez, F. J. et al. Idiopathic pulmonary fibrosis. Nat. Rev. Dis. Primers 3, 17074 (2017).
  • Akhter, N. & Rizvi, N. Interstitial lung diseases misdiagnosed as tuberculosis. Eur. Respir. J. 50, PA2716 (2018).
  • Gerke, A. K., Judson, M. A., Cozier, Y. C., Culver, D. A. & Koth, L. L. Disease burden and variability in sarcoidosis. Ann. Am. Thorac. Soc. 14, S421–S428 (2017).
  • Schaub, B., Lauener, R. & von Mutius, E. The many faces of the hygiene hypothesis. J. Allergy Clin. Immunol. 117, 969–977 (2006).
  • Spagnolo, P. & Schwartz, D. A. Genetic predisposition to sarcoidosis: another brick in the wall. Eur. Respir. J. 41, 778–780 (2013).
  • Chowdhury, N. U., Guntur, V. P., Newcomb, D. C. & Wechsler, M. E. Sex and gender in asthma. Eur. Respir. Rev. 30, 210067 (2021).
  • Zein, J. G. et al. Benefits of airway androgen receptor expression in human asthma. Am. J. Respir. Crit. Care Med. 204, 285–293 (2021).
  • Azoulay, E. et al. Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Med. 46, 298–314 (2020).
  • Guillo, E. et al. COVID-19 pneumonia: diagnostic and prognostic role of CT based on a retrospective analysis of 214 consecutive patients from Paris, France. Eur. J. Radiol. 131, 109209 (2020).
  • Kim, M. S. et al. Long-term autoimmune inflammatory rheumatic outcomes of COVID-19. Ann. Intern. Med. 177, 291–302 (2024).
  • Alqahtani, J. S. et al. Reduction in hospitalised COPD exacerbations during COVID-19: a systematic review and meta-analysis. PLoS ONE 16, e0255659 (2021).
  • Sykes, D. L., Faruqi, S., Holdsworth, L. & Crooks, M. G. Impact of COVID-19 on COPD and asthma admissions, and the pandemic from a patient's perspective. ERJ Open Res. 7, 00822–2020 (2021).
  • Brooks, J. T. & Butler, J. C. Effectiveness of mask wearing to control community spread of SARS-CoV-2. JAMA 325, 998–999 (2021).
  • Lee, H. et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur. Respir. J. 58, 2004125 (2021).
  • Choi, Y. et al. Acute and post-acute respiratory complications of SARS-CoV-2 infection: population-based cohort study in South Korea and Japan. Nat. Commun. 15, 4499 (2024).
  • Oh, J. et al. Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK. Nat. Commun. 15, 2830 (2024).
  • Izquierdo, J. L. et al. The impact of COVID-19 on patients with asthma. Eur. Respir. J. 57, 2003142 (2021).
  • Yang, J. M. et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J. Allergy Clin. Immunol. 146, 790–798 (2020).
  • Aveyard, P. et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir. Med. 9, 909–923 (2021).
  • Boehm, A. et al. Assessing global COPD awareness with Google Trends. Eur. Respir. J. 53, 1900351 (2019).
  • Kennedy, B. K. et al. Geroscience: linking aging to chronic disease. Cell 159, 709–713 (2014).
  • Balmes, J. R. Household air pollution from domestic combustion of solid fuels and health. J. Allergy Clin. Immunol. 143, 1979–1987 (2019).
  • Ramirez, C. et al. Achieving Nepal's clean cooking ambitions: an open source and geospatial cost–benefit analysis. Lancet Planet Health 8, e754–e765 (2024).
  • Alupo, P. et al. Overcoming challenges of managing chronic obstructive pulmonary disease in low- and middle-income countries. Expert Rev. Respir. Med. 18, 873–882 (2024).
  • Naghavi, M. et al. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1811–1872 (2025).
  • Harari, S. et al. Fibrotic interstitial lung diseases and air pollution: a systematic literature review. Eur. Respir. Rev. 29, 200093 (2020).
  • Brauer, M. et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403, 2162–2203 (2024).
  • Kim, M. S. et al. Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Glob. Health 11, e1553–e1565 (2023).
  • Pérez, A., Valencia, S., Jani, P. P. & Harrell, M. B. Use of electronic nicotine delivery systems and age of asthma onset among US adults and youths. JAMA Netw. Open 7, e2410740 (2024).
  • GBD 2021 Diseases and Injuries Collaborators Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403, 2133–2161 (2024).
  • Shin, Y. H. et al. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Allergy 78, 2232–2254 (2023).
  • Patwardhan, V. et al. Differences across the lifespan between females and males in the top 20 causes of disease burden globally: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Public Health 9, e282–e294 (2024).
  • Kim, S. et al. Global, regional, and national trends in drug use disorder mortality rates across 73 countries from 1990 to 2021, with projections up to 2040: a global time-series analysis and modelling study. eClinicalMedicine 79, 102985 (2025).
  • Wang, H. et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet 399, 1513–1536 (2022).
  • Lee, S. et al. Global, regional, and national trends in maternal mortality ratio across 37 high income countries from 1990 to2021, with projections up to 2050: a comprehensive analysis from the WHO Mortality Database. J. Korean Med. Sci. 40, e85 (2025).
  • GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789–1858 (2018).
  • Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease Study 2021 (GBD 2021) Socio-Demographic Index (SDI) 1950–2021 (IHME, 2024).